The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2022 | Advances in ALK-mutant NSCLC
Alessandra Bearz, MD, CRO National Cancer Institute, Aviano, Italy, discusses advances in ALK-mutant non-small cell lung cancer (NSCLC), the development of second and third-generation ALK inhibitors to overcome resistance, as well as novel compounds under investigation. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
